ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS

INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2021

4.	INTANGIBLE ASSETS

Intangible assets at June 30, 2021 and December 31, 2020 consist of the following:

	June 30, 2021						December 31, 2020
	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
Trademark and other intangible rights related to Nabi-HB	$	4,100,046	$	2,391,693	$	1,708,353	$	4,100,046	$	2,098,833	$	2,001,213
Rights to intermediates		907,421		529,329		378,092		907,421		464,513		442,908
Customer contract		1,076,557		1,076,557		-		1,076,557		1,076,557		-
	$	6,084,024	$	3,997,579	$	2,086,445	$	6,084,024	$	3,639,903	$	2,444,121

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets was $0.2 million for the three months ended June 30, 2021 and 2020, and $0.4 million for the six months ended June 30, 2021 and 2020. Estimated aggregate future aggregate amortization expense is expected to be as follows:

2021	$	357,676
2022		715,352
2023		715,352
2024		298,065